Early Aspirin Withdrawal After PCI in ACS: NEO-MINDSET and TARGET Trials
Christopher Cannon, Senior Physician in the Cardiovascular Division at Brigham and Women’s Hospital, shared a post on LinkedIn:
”Keep the ASA for the first 12 months post ACS PCI.
The NEO-MINDSET trial found that early stopping and keeping P2Y12 monotherapy was NOT sufficient for efficacy.
Of note, another study published, the TARGET First looked at “low risk” STEMI patients and suggested one could stop ASA, but it appeared to have much less power with just 41 primary endpoints.
So – I will aim to keep DAPT for a year post PCI for ACS. (although sometimes one has to adapt for very high risk bleeding patients).”
Title: Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes
Authors: Patricia O. Guimarães, Marcelo Franken, Caio A.M. Tavares, Murillo O. Antunes, Fabio S. Silveira, Pedro B. Andrade, Ricardo R. Bergo
Read the full article here.
Find more on Hemostasis Today.
-
Jul 7, 2026, 23:20Balaji Balagani: Exploring Pulmonary Embolism
-
Jul 7, 2026, 23:03Roxana González Mazarío: The Phenotype-Specific Cardiovascular Risks in AAV
-
Jul 7, 2026, 22:52Harry Spoelstra: LongC0VID Still has Zero Proven Treatments
-
Jul 7, 2026, 22:39Satya K. Morar: Acute Portal Vein Thrombosis as an Exceptionally Rare Complication of Liver Biopsy in CVID
-
Jul 7, 2026, 22:23Aravind Palraj: Antiphospholipid Syndrome is not Just ‘Start Warfarin and Follow INR’
-
Jul 7, 2026, 20:59William Aird: An Unlucky Turn Into the Renal Artery
-
Jul 7, 2026, 20:58Chokri Ben Lamine: The Two-Hit Model of TRALI
-
Jul 7, 2026, 20:57New Issue of Blood Out Now – Blood Journals Portfolio
-
Jul 7, 2026, 20:56Priyadarshini Ramakrishnan: Schistocytes – The Most “Misleading Heroes” in a Peripheral Smear